Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA026817 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA026817, RRID:AB_1855044
- Product name
- Anti-PCDH17
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human PCDH17, Gene description: protocadherin 17, Alternative Gene Names: PCDH68, PCH68, Validated applications: ICC, IHC, Uniprot ID: O14917, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references PCDH17 increases the sensitivity of colorectal cancer to 5-fluorouracil treatment by inducing apoptosis and autophagic cell death
p53/PCDH17/Beclin-1 Proteins as Prognostic Predictors for Urinary Bladder Cancer
Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer
Liu S, Lin H, Wang D, Li Q, Luo H, Li G, Chen X, Li Y, Chen P, Zhai B, Wang W, Zhang R, Chen B, Zhang M, Han X, Li Q, Chen L, Liu Y, Chen X, Li G, Xiang Y, Duan T, Feng J, Lou J, Huang X, Zhang Q, Pan T, Yan L, Jin T, Zhang W, Zhuo L, Sun Y, Xie T, Sui X
Signal Transduction and Targeted Therapy 2019;4(1)
Signal Transduction and Targeted Therapy 2019;4(1)
p53/PCDH17/Beclin-1 Proteins as Prognostic Predictors for Urinary Bladder Cancer
Chen L, Liu Y, Zhang Q, Zhang M, Han X, Li Q, Xie T, Wu Q, Sui X
Journal of Cancer 2019;10(25):6207-6216
Journal of Cancer 2019;10(25):6207-6216
Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer
Yin X, Xiang T, Mu J, Mao H, Li L, Huang X, Li C, Feng Y, Luo X, Wei Y, Peng W, Ren G, Tao Q
Oncotarget 2016;7(32):51720-51732
Oncotarget 2016;7(32):51720-51732
No comments: Submit comment
No validations: Submit validation data